{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=6", "query": { "condition": "Advanced Solid Tumor and Lymphoma Malignancies", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 336, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:55:48.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03775525", "title": "Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Gastric Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer Metastatic", "Colo-rectal Cancer", "Solid Tumor", "Solid Carcinoma", "Solid Carcinoma of Stomach", "Cancer of Stomach", "Lymphoma", "Sarcoma", "Cutaneous T Cell Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Basal Cell Carcinoma", "Cutaneous T-cell Lymphoma", "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "GZ17-6.02", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzada Pharmaceuticals USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2019-03-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-12-23", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775525" }, { "nct_id": "NCT06390865", "title": "Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-03-12", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06390865" }, { "nct_id": "NCT03454243", "title": "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "RXDX-106", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-15", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454243" }, { "nct_id": "NCT01051635", "title": "A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Lymphoma" ], "interventions": [ { "name": "LMP400", "type": "DRUG" }, { "name": "LMP776", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2010-01-25", "completion_date": "2017-06-21", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01051635" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT00323934", "title": "Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "MGCD0103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-04", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323934" }, { "nct_id": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Carcinoma", "Adenoid Cystic Carcinoma", "Lung Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Mesothelioma", "Esophageal Cancer", "Any Solid Tumors Progressed After a Prior Immunotherapy", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma HNSCC", "Salivary Gland Carcinomas", "Head and Neck Cancers - Salivary Gland", "Head and Neck Cancers - Nasopharyngeal", "Head and Neck Cancers - Throat", "Small Cell Lung Cancer ( SCLC )", "Lung Cancer (Locally Advanced or Metastatic)", "Head and Neck Cancers - Tonsils", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Lip", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Trachea" ], "interventions": [ { "name": "VMD-928 100 mg Tablet", "type": "DRUG" }, { "name": "VMD-928 Tablet and Pembrolizumab (200 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 242, "start_date": "2018-06-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 14, "location_summary": "Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556228" }, { "nct_id": "NCT00725634", "title": "A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumor", "Lymphomas", "Multiple Myeloma" ], "interventions": [ { "name": "AV-299", "type": "BIOLOGICAL" }, { "name": "AV-299 + erlotinib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2008-09", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-01-27", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Columbus, Ohio • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725634" }, { "nct_id": "NCT00004212", "title": "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "1999-09", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 4, "location_summary": "New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004212" }, { "nct_id": "NCT03538028", "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Microsatellite Instability (MSI)-High Endometrial Cancer", "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma (Uveal Melanoma Excluded)", "Merkel Cell Carcinoma", "Mesothelioma", "MSI-high Colorectal Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Small Cell Lung Cancer (SCLC)", "Renal Cell Carcinoma (RCC)", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "INCAGN02385", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-06-18", "completion_date": "2020-10-07", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-14T04:55:48.901Z", "location_count": 4, "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538028" } ] }